Successful reversal of advanced heart failure due to peripartum cardiomyopathy with aggressive pharmacotherapy and a continuous‑flow left ventricular assist device (RCD code: III-1B.8c)
Full Text:
Abstract
Peripartum cardiomyopathy (PPCM) is a rare but potentially devastating complication of pregnancy. PPCM is not well understood and relatively little is known about its epidemiology and pathogenesis. However, it appears to have a more favourable prognosis compared with other causes of heart failure (HF) with a significant proportion of patients experiencing recovery of left ventricular (LV) function. As such, the optimal therapeutic strategy in severely affected patients is not clear currently. We report a case of severe PPCM in a 19‑year‑old woman who was managed successfully with implantation of a left ventricular assist device and aggressive pharmacotherapy with the aim of promoting myocardial recovery. She experienced marked improvement in both symptoms and left ventricular function which was sustained following LVAD explantation. JRCD 2013; 1 (5): 17–19
Keywords
References
Birks EJ, Tansley PD, Hardy J et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006; 355: 1873–1884.
Birks EJ, George RS, Hedger M et al. Reversal of severe heart failure with a continuous‑flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011; 123: 381–390.
Haj‑Yahia S, Birks EJ, Dreyfus G et al. Limited surgical approach for explanting the HeartMate II left ventricular assist device after myocardial recovery. J Thorac Cardiovasc Surg. 2008; 135: 453–454.
Dalzell JR, Jackson CE, Gardner RS. An update on peripartum cardiomyopathy. Expert Rev Cardiovasc Ther. 2011; 9: 1155 1160.
Sliwa K, Hilfiker‑Kleiner D, Petrie MC et al. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010; 12: 767–778.
Felker GM, Thompson RE, Hare JM et al. Underlying causes and long‑term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342: 1077–1084.
Loyaga‑Rendon RY, Pamboukian SV, Tallaj JA et al. Outcomes of Patients with Peripartum Cardiomyopathy Who Received Mechanical Circulatory Support: Data from the INTERMACS Registry. Circ Heart Fail. 2014; 7: 300–309.
DOI: http://dx.doi.org/10.20418%2Fjrcd.vol1no5.54
Refbacks
- There are currently no refbacks.